Novartis' Lucentis could gain from German review of diabetes clinical guidelines
This article was originally published in Scrip
IQWiG, Germany's Institute of Quality and Efficiency in Healthcare, is recommending some revision to the disease management programme for type 1 diabetes, which could be good news for Novartis' VEGF receptor antagonist Lucentis (ranibizumab), among other diabetic macular oedema treatments.
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.